Trial Profile
Effect of Saxagliptin in Addition to Dapagliflozin and Metformin on Insulin Resistance, Islet Cell Dysfunction, and Metabolic Control in Subjects with Type 2 Diabetes Mellitus on Previous Metformin Treatment
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Oct 2018
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary) ; Saxagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- 13 Jun 2017 Results presented at the 77th Annual Scientific Sessions of the American Diabetes Association.
- 03 Nov 2016 Status changed from recruiting to completed.
- 27 Dec 2014 New trial record